← Leaderboards
Vijayakanth Pagadala
Glycan Therapeutics Corporation
$12,153,122
Attributed
$12,380,622
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,380,622 · 6
By mechanism
R44$9,979,081 · 3
N44$1,646,541 · 1
R41$455,000 · 1
R43$300,000 · 1
Top collaborators
- Katelyn Arnold3 shared
Most similar at Glycan Therapeutics Corporation
Same institution · by research overlap
- Katelyn Arnold$1,234,308
- Zhangjie Wang$4,365,125
- Quin Shi$299,447
Others in their field
Top investigators on “Polysaccharides”
- Barton F Haynes · Duke University$271,280,523
- James C. Paulson · Scripps Research Institute$26,939,993
- George M Shaw · University Of Pennsylvania$26,084,324
- Arturo Casadevall · Johns Hopkins University$24,878,303
- Pamela J Bjorkman · California Institute Of Technology$23,198,758
- Ajit P Varki · University Of California San Diego$23,013,837
Research focus
PolysaccharidesStructureHeparinProductionPreparationDesignOligosaccharidesTechnologySmall Business Innovation Research GrantInnovationSulfatePhase 2 StudyAnticoagulantsScale UpCost EffectiveBaseLabelAnimalsPharmaceutical PreparationsDepolymerizationInvestigational DrugsAnimal TissueClinical TrialsIntestines
Grant awards (17)
Development of anticoagulant sulfated glycans$1,061,433
R44 · FY2025 · GM · contact PI
Development of dekaparin to replace animal-sourced heparin$991,212
R44 · FY2025 · HL · contact PI
Development of anticoagulant sulfated glycans$1,090,303
R44 · FY2024 · GM · contact PI
Development of dekaparin to replace animal-sourced heparin$747,280
R44 · FY2024 · HL · contact PI
National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation$55,000
R41 · FY2024 · CA
Development of anticoagulant sulfated glycans$355,989
R44 · FY2023 · GM · contact PI
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation$251,076
R41 · FY2023 · CA
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation$148,924
R41 · FY2023 · CA
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$1,200,327
R44 · FY2021 · GM · contact PI
Quantitative analysis of heparan sulfate using 13C-labeled standards$300,000
R43 · FY2021 · GM · contact PI
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$272,811
R44 · FY2021 · GM · contact PI
Development of a New Carbohydrate-based Anticoagulant Drug$1,248,861
R44 · FY2020 · HL · contact PI
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$1,229,662
R44 · FY2020 · GM · contact PI
Development of a New Carbohydrate-based Anticoagulant Drug$1,244,412
R44 · FY2019 · HL · contact PI
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans$536,791
R44 · FY2019 · GM · contact PI
IGF::OT::IGF CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES$693,710
N44 · FY2017 · CA · contact PI
IGF::OT::IGF CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES$952,831
N44 · FY2015 · CA · contact PI